Log In
Print
BCIQ
Print
Print this Print this
 

PF-05280586

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat moderate to severe active rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today